Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematous.


Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Nov 2021
Historique:
pubmed: 20 11 2021
medline: 24 2 2022
entrez: 19 11 2021
Statut: ppublish

Résumé

The evaluation of Patient Reported Outcomes Measurement Information System (PROMIS) computerized adaptive test (CAT) in adults with systemic lupus erythematous (SLE) is an emerging field of research. We aimed to examine the test-retest reliability and construct validity of the PROMIS CAT in a Canadian cohort of patients with SLE. Two hundred twenty-seven patients completed 14 domains of PROMIS CAT and seven legacy instruments during their clinical visits. Test-retest reliability of PROMIS was evaluated 7-10 days from baseline using intraclass correlation coefficient (ICC (2; 1)). The construct validity of the PROMIS CAT domains was evaluated against the commonly used legacy instruments, and also in comparison to disease activity and disease damage using Spearman correlations. A multitrait-multimethod matrix (MMM) approach was used to further assess construct validity comparing selected 10 domains of PROMIS and SF-36 domains. Moderate to excellent reliability was found for all domains (ICC [2;1] ranging from lowest, 0.66 for Sleep Disturbance and highest, 0.93 for the Mobility domain). Comparing seven legacy instruments with 14 domains of PROMIS CAT, moderate to strong correlations (0.51-0.91) were identified. The average time to complete all PROMIS CAT domains was 11.7 min. The MMM further established construct validity by showing moderate to strong correlations (0.55-0.87) between select PROMIS and SF-36 domains; the average correlations from similar traits (convergent validity) were significantly greater than the average correlations from different traits. These results provide evidence on the reliability and validity of PROMIS CAT in SLE in a Canadian cohort.

Sections du résumé

BACKGROUND BACKGROUND
The evaluation of Patient Reported Outcomes Measurement Information System (PROMIS) computerized adaptive test (CAT) in adults with systemic lupus erythematous (SLE) is an emerging field of research. We aimed to examine the test-retest reliability and construct validity of the PROMIS CAT in a Canadian cohort of patients with SLE.
METHODS METHODS
Two hundred twenty-seven patients completed 14 domains of PROMIS CAT and seven legacy instruments during their clinical visits. Test-retest reliability of PROMIS was evaluated 7-10 days from baseline using intraclass correlation coefficient (ICC (2; 1)). The construct validity of the PROMIS CAT domains was evaluated against the commonly used legacy instruments, and also in comparison to disease activity and disease damage using Spearman correlations. A multitrait-multimethod matrix (MMM) approach was used to further assess construct validity comparing selected 10 domains of PROMIS and SF-36 domains.
RESULTS RESULTS
Moderate to excellent reliability was found for all domains (ICC [2;1] ranging from lowest, 0.66 for Sleep Disturbance and highest, 0.93 for the Mobility domain). Comparing seven legacy instruments with 14 domains of PROMIS CAT, moderate to strong correlations (0.51-0.91) were identified. The average time to complete all PROMIS CAT domains was 11.7 min. The MMM further established construct validity by showing moderate to strong correlations (0.55-0.87) between select PROMIS and SF-36 domains; the average correlations from similar traits (convergent validity) were significantly greater than the average correlations from different traits.
CONCLUSIONS CONCLUSIONS
These results provide evidence on the reliability and validity of PROMIS CAT in SLE in a Canadian cohort.

Identifiants

pubmed: 34797991
doi: 10.1177/09612033211051275
pmc: PMC8649426
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2102-2113

Références

Neuropsychiatr Dis Treat. 2018 Oct 29;14:2861-2877
pubmed: 30464471
J Rheumatol. 2006 Dec;33(12):2453-7
pubmed: 17143980
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Med Care. 1993 Mar;31(3):247-63
pubmed: 8450681
J Rheumatol. 2014 Jan;41(1):153-8
pubmed: 24241485
Arthritis Rheum. 2006 Jun 15;55(3):434-41
pubmed: 16739211
J Orthop Trauma. 2014 Aug;28(8):439-43
pubmed: 24378399
Psychol Bull. 1959 Mar;56(2):81-105
pubmed: 13634291
Clin Neuropsychol. 2004 Feb;18(1):132-47
pubmed: 15595365
Arthritis Rheum. 2009 Sep 15;61(9):1179-86
pubmed: 19714612
Lupus Sci Med. 2020 Jun;7(1):
pubmed: 32591423
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S413-9
pubmed: 22588761
Br J Math Stat Psychol. 2011 Feb;64(Pt 1):38-52
pubmed: 21506944
J Rheumatol. 2011 Apr;38(4):672-9
pubmed: 21239746
Rheumatology (Oxford). 2020 Nov 1;59(11):3211-3220
pubmed: 32221602
Med Care. 1994 Jan;32(1):40-66
pubmed: 8277801
J Ment Health Policy Econ. 2011 Dec;14(4):201-8
pubmed: 22345362
Semin Arthritis Rheum. 2019 Oct;49(2):260-266
pubmed: 30940467
Arthritis Care Res (Hoboken). 2017 Jan;69(1):133-142
pubmed: 27111350
Arthritis Care Res (Hoboken). 2018 Jan;70(1):104-113
pubmed: 28371529
Am J Sports Med. 2014 Dec;42(12):2906-16
pubmed: 25288625
Support Care Cancer. 2015 May;23(5):1355-64
pubmed: 25351456
J Rheumatol. 2017 Jul;44(7):1024-1031
pubmed: 28412708
J Rheumatol. 2020 Aug 1;47(8):1182-1188
pubmed: 31371654
J Clin Epidemiol. 2010 Nov;63(11):1179-94
pubmed: 20685078
Rheumatology (Oxford). 2013 Apr;52(4):684-96
pubmed: 23264550
Health Qual Life Outcomes. 2014 Jul 22;12:116
pubmed: 25048687
Lupus. 2011 Jan;20(1):35-43
pubmed: 21233148
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Lupus. 2010 Jan;19(1):49-51
pubmed: 19910390
Arthritis Care Res (Hoboken). 2018 Jan;70(1):125-133
pubmed: 28320078
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
J Rheumatol. 2000 Feb;27(2):373-6
pubmed: 10685799
Lupus Sci Med. 2018 Aug 21;5(1):e000279
pubmed: 30167315
Arthritis Rheumatol. 2014 Oct;66(10):2900-8
pubmed: 24964773
PLoS One. 2015 Sep 17;10(9):e0138543
pubmed: 26379233
J Rheumatol. 2018 Mar;45(3):397-404
pubmed: 29419473
Qual Life Res. 2016 Aug;25(8):2109-16
pubmed: 26914103
Ann Rheum Dis. 2015 Jan;74(1):104-7
pubmed: 24095937

Auteurs

Mitra Moazzami (M)

Department of Medicine, 43989The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Patricia Katz (P)

Department of Medicine and Health Policy, 8785University of California San Francisco, San Francisco, CA, USA.

Dennisse Bonilla (D)

Division of Rheumatology, Department of Medicine, Toronto Western Hospital-Lupus Clinic, 7989University Health Network, Toronto, ON, Canada.

Lisa Engel (L)

Department of Occupational Therapy, College of Rehabilitation Sciences, Rady Faculty of Health Sciences, 8664University of Manitoba, Winnipeg, MB, Canada.

Jiandong Su (J)

Centre for Prognosis Studies in the Rheumatic Diseases, 7989University Health Network, Toronto, ON, Canada.

Pooneh Akhavan (P)

Division of Rheumatology, Department of Medicine, Mount Sinai Hospital, 12366University of Toronto Faculty of Medicine, Toronto, ON, Canada.

Nicole Anderson (N)

Division of Rheumatology, Department of Medicine, Toronto Western Hospital-Lupus Clinic, 7989University Health Network, Toronto, ON, Canada.

Oshrat E Tayer-Shifman (OE)

Rheumatology Service, 37253Meir Medical Center, Kfar-Saba, Israel.

Dorcas Beaton (D)

Health Measurement, St. Michael's Hospital, University of Toronto, 7966Institute for Work and Health, Toronto, ON, Canada.

Zahi Touma (Z)

Division of Rheumatology, Department of Medicine; Toronto Western Hospital-Lupus Clinic; Institute of Health Policy, Management and Evaluation, 7938University of Toronto, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH